AGE metabolites: A biomarker linked to cancer disparity?

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 10, 2014, Pages 2186-2191

  Foster, Dion ^a   Spruill, Laura ^a   Walter, Katherine R ^a   Nogueira, Lourdes M ^a   Fedarovich, Hleb ^a   Turner, Ryan Y ^a   Ahmed, Mahtabuddin ^b   Salley, Judith D ^b   Ford, Marvella E ^c   Findlay, Victoria J ^a,c   Turner, David P ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SOUTH CAROLINA STATE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; TUMOR MARKER;

AFRICAN AMERICAN; ARTICLE; CANCER DISPARITY; CANCER GROWTH; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; EUROPEAN AMERICAN; GLEASON SCORE; HEALTH DISPARITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; METABOLITE; PROSTATE CANCER; PROTEIN EXPRESSION; SEDENTARY LIFESTYLE; CAUCASIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; METABOLISM; PROSTATE TUMOR;

AFRICAN AMERICANS; BIOMARKERS, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS;

EID: 84907564529     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0564     Document Type: Article

References (25)

1. Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, et al. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer 2014;134:81-91.
2. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol 2013;25:235-41.
3. Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol 2013;27: 879-91.
4. Reams RR, Agrawal D, Davis MB, Yoder S, Odedina FT, Kumar N, et al. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer 2009;4 Suppl 1:S3.
5. Research. WCRFAIfC. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR; 2007.
6. Avery KN, Donovan JL, Horwood J, Neal DE, Hamdy FC, Parker C, et al. The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. BMC Fam Pract 2014;15:81.
7. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 2005;14:275-9.
8. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011;29:726-32.
9. Ansari NA, Rasheed Z. [Non-enzymatic glycation of proteins: from diabetes to cancer]. Biomed Khim 2010;56:168-78.
10. Duran-Jimenez B, Dobler D, Moffatt S, Rabbani N, Streuli CH, Thornalley PJ, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009;58:2893-903.
11. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal 2009;7:12.
12. Rojas A, Gonzalez I, Morales E, Perez-Castro R, Romero J, Figueroa H. Diabetes and cancer: Looking at the multiligand/RAGE axis. World J Diabetes 2011;2:108-13.
13. Allmen EU, Koch M, Fritz G, Legler DF. V domain ofRAGE interacts with AGEs on prostate carcinoma cells. Prostate 2008;68:748-58.
14. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-6 e12.
15. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005;1043:452-60.
16. Yoshikawa T, Miyazaki A, Fujimoto S. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. Med Sci Monit 2009;15: PH65-73.
17. Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58:1669-77.
18. Ames JM. Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. Ann N Y Acad Sci 2008;1126:20-4.
19. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
20. Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland MC, Kajdacsy-Balla A, et al. Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun 2012;417:1133-8.
21. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100.
22. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
23. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014;23: 847-56.
24. Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010; 8:70.
25. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.